Papers
15
Total Citations
169
H-Index
9
About
Stephan Buse is a leading urologic surgeon and researcher whose work centers on advancing robot-assisted surgery for complex urologic cancers and pelvic reconstruction. His major contributions include landmark randomized controlled trials, such as the OpeRa trial (NCT03849820), which directly compared robotic-assisted versus open partial nephrectomy for intermediate/high-complexity kidney tumors, providing crucial evidence on postoperative outcomes. Buse has also pioneered techniques in robot-assisted radical cystectomy with intracorporeal neobladder reconstruction, systematically reporting functional outcomes—including urinary continence and erectile function—that guide surgical decision-making. His research on cost-effectiveness, with papers accumulating over 20 citations each, has demonstrated the economic viability of robotic approaches, influencing healthcare policy. Beyond oncology, Buse led an international Delphi study to establish consensus on robot-assisted pelvic floor reconstruction, standardizing best practices. During the COVID-19 pandemic, his multicenter assessment of urological care deferral informed clinical triage protocols. With multiple papers exceeding 30 citations and active leadership in the European Robotic Urology Section, Buse’s work has shaped modern urologic practice by rigorously evaluating surgical innovation through both clinical and economic lenses.
Research Focus
Key Achievements
Top Papers
- 1
- 2Cost‐effectiveness analysis of robot‐assisted vs. open partial nephrectomy24 citations · 2018
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10